Mila Pontremoli Salcedo, Assistant Professor at MD Anderson Cancer Center, shared a post on LinkedIn:
“I’m proud to share a meaningful milestone: our PHIL Study has officially enrolled its 1,000th participant. This randomized clinical trial is focused on evaluating ablative treatments to reduce cervical cancer risk among women living with HIV in Mozambique. This is a critical step toward supporting women living with HIV in sub-Saharan Africa – a population that is disproportionately affected by cervical cancer.
As a collaboration between CISPOC INS – DPCM, Hospital Central de Maputo Rice University and UT MD Anderson, and with support from The National Institutes of Health/National Cancer Institute (NCI), this work aims to identify more effective treatment approaches and to reduce treatment failures, ultimately improving outcomes where the need is greatest.
This milestone reflects the dedication of an extraordinary, cross-continental team. I am truly grateful for the leadership and collaboration of our colleagues in Mozambique, Rice University, at UT MD Anderson and at the NIH/NCI: Cesaltina Lorenzoni, Mário Chalyamba, Eliane Monteiro, Nafissa Osman, Ricardina Rangeiro Andrea Neves, Arlete Mariano; Edna Viegas, Edna Carol Nhacule, Guilhermina Tivir, Kathleen Schmeler, Ellen Baker, Jessica Milan, Zohra Kantawala, Melissa Lopez Varon, Elizabeth Chiao, Parisa Fallah, Rebecca Richards-Kortum, Jennifer Carns, Richard Schwarz, Jose Jeronimo, Phil Castle.
It has been an honor to be a part of this team, and I am thankful for the work we continue to do together to End Cancer.”
Other articles featuring Mila Pontremoli Salcedo on OncoDaily.
